In preliminary provisions, further providing for definitions; and, in pharmacy benefits manager contracts, providing for State pharmacy benefits manager.
HB2270 would amend Pennsylvania’s Pharmacy Audit Integrity and Transparency Act to revise the definitions of “specialty drug” and “spread pricing,” and to create a new framework for a single State pharmacy benefits manager (PBM) for Medicaid. Under the bill, the Department of Human Services would be required to select, through competitive procurement, one third-party administrator to administer pharmacy benefits for all Medicaid recipients, including those enrolled in managed care organizations, by July 31, 2026.
The bill also imposes detailed contract rules on the State PBM. It would prohibit the PBM from steering enrollees to affiliated pharmacies, requiring exclusive mail-order or specialty-pharmacy use except where necessary, imposing extra documentation requirements beyond law or regulation, retroactively denying or reducing valid claims, using spread pricing, or charging certain pharmacy fees. It would require pass-through pricing, set reimbursement floors tied to NADAC or wholesale acquisition cost plus dispensing fees, and establish fiduciary duties to the Department of Human Services and participating pharmacies or pharmacists.
HB2270 would significantly change how Medicaid pharmacy benefits are administered in Pennsylvania by centralizing those functions under a single state-selected PBM rather than allowing each managed care organization to use its own arrangement. It would also alter state law governing PBM conduct by tightening definitions, banning spread pricing, requiring pass-through pricing, and limiting fees and claim adjustments that can be imposed on pharmacies. The bill would affect the Department of Human Services, Medicaid managed care organizations, PBMs, pharmacies, pharmacists, and Medicaid enrollees.
Based on the bill text and the absence of recorded committee debate or votes in the provided materials, the bill appears to be framed as a transparency and cost-control measure aimed at pharmacy benefit management in Medicaid. The sponsors listed from both parties suggest an interest in a bipartisan policy approach, and the measure’s structure indicates support for stronger oversight of PBM practices. No contrary sentiment is documented in the supplied record.
The main points of contention likely concern the creation of a single state PBM, the prohibition on spread pricing, and the restrictions on affiliated or mail-order pharmacy steering. Supporters would likely view these provisions as protecting pharmacies and Medicaid recipients from opaque pricing and conflicts of interest, while critics may argue that the bill limits PBM flexibility, could disrupt managed care contracting, and may increase administrative complexity for DHS and MCOs. The reimbursement floor and fiduciary-duty requirements may also be disputed by PBMs and insurers concerned about cost and operational impact.